Surgery – Devices transferring fluids from within one area of body to... – With flow control means
Reexamination Certificate
2006-04-11
2006-04-11
Bianco, Patricia (Department: 3761)
Surgery
Devices transferring fluids from within one area of body to...
With flow control means
C604S008000
Reexamination Certificate
active
07025742
ABSTRACT:
A method treats a patient for adult-onset dementia of the Alzheimer's type by removing a portion of the patient's cerebrospinal fluid, preferably (although not necessarily) by transporting the fluid to another portion of the patient's body. An apparatus for removing cerebrospinal fluid includes (1) a conduit with a first opening and a second opening, the first opening of the conduit being disposed in fluid communication with a space within a patient's subarachnoid space, the second opening being disposed in fluid communication with another portion of the patient's body; and (2) a flow rate control device attached to the conduit.
REFERENCES:
patent: 3654932 (1972-04-01), Newkirk et al.
patent: 3864259 (1975-02-01), Newhart
patent: 3886948 (1975-06-01), Hakim
patent: 4156422 (1979-05-01), Hildebrandt et al.
patent: 4261341 (1981-04-01), Hakim et al.
patent: 4375816 (1983-03-01), Labianca
patent: 4560375 (1985-12-01), Schulte et al.
patent: 4598579 (1986-07-01), Cummings et al.
patent: 4605395 (1986-08-01), Rose et al.
patent: 4610658 (1986-09-01), Buchwald et al.
patent: 4673384 (1987-06-01), Marion
patent: 4675003 (1987-06-01), Hooven
patent: 4681559 (1987-07-01), Hooven
patent: 4713065 (1987-12-01), Koot
patent: 4933156 (1990-06-01), Quay et al.
patent: 4950232 (1990-08-01), Ruzicka et al.
patent: 5039511 (1991-08-01), Quay
patent: 5069663 (1991-12-01), Sussman
patent: 5167615 (1992-12-01), East et al.
patent: 5334315 (1994-08-01), Matkovich et al.
patent: 5336166 (1994-08-01), Sierra
patent: 5368556 (1994-11-01), Lecuyer
patent: 5385541 (1995-01-01), Kirsch et al.
patent: 5387188 (1995-02-01), Watson
patent: 5425368 (1995-06-01), Brandt
patent: 5462667 (1995-10-01), Wollinsky et al.
patent: 5601985 (1997-02-01), Trojanowski et al.
patent: 5643194 (1997-07-01), Negre
patent: 5643195 (1997-07-01), Drevet et al.
patent: 5980480 (1999-11-01), Rubenstein et al.
patent: 115973 (1984-08-01), None
patent: 117695 (1984-09-01), None
patent: 478842 (1992-04-01), None
patent: 2354103 (1978-01-01), None
patent: 2685206 (1993-06-01), None
Adams et al., “Disturbances of cerebrospinal fluid circulation, including hydrocephalus and meningeal reactions,”Principles of Neurology, Fourth Edition, Chapter 30, 1989, pp. 501-502.
Adams, R.D. et al., “Symptomatic occult hydrocephalus with ‘normal’ cerebrospinal-fluid pressure”The New England Journal of Medicine, vol. 273, No. 3, pp. 117-126 (Jul. 15, 1965).
Appenzeller, Otto & Salmon, James H., Treatment of parenchymatous degeneration of the brain by ventriculo-atrial shunting of the cerebrospinal fluid,Journal of Neurosurgery, vol. XXVI, pp. 478-482, (Jan.-Jun. 1967).
Arai et al., “Tau in cerebrospinal fluid: a potential diagnostic marker,”Ann. Neurology, vol. 38, 1995, pp. 649-652.
Bannister, Roger, et al., “Isotope encephalography in the diagnosis of dementia due to communicating hydrocephalus”The Lancet, pp. 1014-1017, (Nov. 11, 1967).
Barnett et al., “Normal pressure hydrocephalus in children and young adults”Neurosurgery(1987) 20(6):904-907.
Boon et al., “Does CSF outflow resistance predict the response to shunting in patients with normal pressure hydrocephalus?”Acta Neurochir. (1998) 71:331-333.
Boon et al., “Dutch normal-pressure hydrocephalus study: Prediction of outcome after shunting by resistance to outflow of cerebrospinal fluid”J. Neurosurg. (1997) 87:687-693
Bush et al., “Beta A-4 amyloid protein and its precursor in Alzheimer's disease,”Pharmac. Tera., vol. 56, 1992, pp. 97-117.
Chen, I.H. et al., “Effectiveness of shunting in patients with normal pressure hydrocephalus predicted by temporary, controlled-resistance, continuous lumbar drainage: a pilot study,”Journal of Neurology, Neurosurgery, and Psychiatry, 1994, S/1430-1432.
Clarfield, “Normal-pressure hydrocephalus: Saga or swamp?”JAMA(1989) 262(18):2592-2593.
Damasceno et al., “The predictive value of cerebrospinal fluid tap-test in normal pressure hydrocephalus”Arq. Neurosiquiatr. (1997) 55(2):179-185.
Friedland, “Normal-pressure hydrocephalus and the saga of the treatable dementias”JAMA(1989) 262(18):2577-2581.
Golomb et al., “Alzheimer's disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response”J. Neurol. Neurosurg. Psych. (2000) 68:778-781.
Graff-Radford et al., “Normal-pressure hydrocephalus”Neurol. (1986) 43:940-942.
Gustafson et al., “Recovery in hydrocephalic dementia after shunt operation”J. Neurol. Neurosurg. Psych. (1978) 41:940-947.
Hakim et al., “The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics”J. Neurol. Sci. (1965) 2:307-327.
Holodny et al., “Focal dilation and paradoxical collapse of cortical fissures and sulci in patients with normal-pressure hydrocephalus” J. Neurosurg. (1998) 89:742-747.
Kaye et al., “Plasticity in the aging brain”Arch Neurol. (1990) 47:1336-1341.
Ko et al., “Cerebrospinal fluid control system” Proceedings of the IEEE, vol. 76, No. 9, pp. 1226-1235, Sep. 1988.
Martinez et al., “Relationship of interleukin-1 beta and beta2-microglobulin with neuropeptides in cerebrospinal fluid of patients with dementia of the Alzheimer type,”J. Neuroimmunology, vol. 48, 1993, pp 235-240.
Mataró et al., “Cognitive changes after cerebrospinal fluid shunting in young adults with spina bifida and assumed arrested hydrocephalus”J. Neurol. Neurosurg. Psych. (2000) 68:615-621.
Mogilner et al., “Hydorcephalus: Does coexistent Alzheimer's disease affect outcome?”Poster Presentation from AANS1999 New Orleans, http://cnshome.org/abstrats, 2 pages total.
Nakamura et al., “Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease,”Ann. Neurology, vol. 36, 1994, pp. 903-911.
Ono et al., “Formation of amyloid-like substance from beta-2-microglobulin in vitro. Role of serum amyloid P component: a preliminary study,”Nephron. vol. 66, 1994, pp. 404-407.
Salmon, James H., “Senile and presenile dementia”Geriatrics(Dec. 1969) 24 (12) : 67-72.
Shenkin et al., “Ventricular shunting for relief of senile symptoms”JAMA(1973) 225(12):1486-1489.
SkinhØj, Erik, “Determination of regional cerebral bloodflow in man” Head injury conference proceedings, held at the University of Chicago Center for Continuing Education with Joseph P. Evans as host. No. 34, pp. 431-438.
Vanneste et al., “Shunting normal-pressure hyrocephalus: Do the benefits outweigh the risks?”Neurol. (1992) 42:54-59.
Vorstrup et al., “Cerebral blod flow in patients with normal-pressure hydrocephalus before and after shunting”J. Neurol. (1987) 66:379-387.
Williams et al., “Evaluation of shunt function in patients who are never better, or better than worse after shunt surgery for NPH”Acta Neurochir. (1998) 71:368-370.
Williams et al., “Comparison of Pcsf monitoring and controlled CSF drainage diagnose normal pressure hydrocephalus”Acta Neurochir. (1998) 71:328-330.
Committee on Medical Rating of Physical Impairment (McKeown, Raymond M. et al.,) “The Central Nervous System,JAMA, The Journal” Fifth in a series pp. 24-35, (Jul. 6, 1963).
Karshmer David L.
Levinthal Elliott C.
Rubenstein Edward
Saul Tom A.
Vargas Jaime S.
Bianco Patricia
Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd
Integra LifeSciences Corporation
LandOfFree
Internally powered CSF pump systems and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Internally powered CSF pump systems and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Internally powered CSF pump systems and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3620186